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OBJECTIVES The purpose of this study was to define appropriate parameters for risk stratification and
prognosis in patients undergoing stress echocardiography.
BACKGROUND Stress echocardiography is an established technique for the diagnosis of coronary artery
disease. However, current data on risk stratification of patients undergoing stress echocardi-
ography are limited.
METHODS We evaluated 1,500 patients (59  13 years old; 51% male) undergoing stress echocardiog-
raphy (34% with treadmill exercise and 66% with dobutamine). Resting left ventricular
ejection fraction (EF) and regional wall motion were assessed by the consensus of two
echocardiographers. Follow-up (mean 2.7  1.0 years) for confirmed non-fatal myocardial
infarction (n  31) and cardiac death (n  44) were performed.
RESULTS By univariate analysis, both the peak wall motion score index (WMSI) (p  0.0001) and EF
(p  0.0001) were significant predictors of cardiac events. Peak WMSI effectively risk
stratified patients into low (0.9%/year), intermediate (3.1%/year), and high (5.2%/year) risk
groups (p  0.0001). A threshold of 45% EF provided further risk stratification of all WMSI
groups. By multivariate logistic regression analysis, peak WMSI (relative risk [RR] 2.1, 95%
confidence interval [CI] 1.0 to 4.4; p  0.04) and EF (RR 1.0, 95% CI 0.9 to 1.0; p  0.01)
were both predictors of cardiac events.
CONCLUSIONS Stress echocardiography yields prognostic information for risk stratification of patients with
known or suspected ischemic heart disease. A normal stress echocardiographic study (peak
WMSI  1.0) confers a benign prognosis (0.9%/year cardiac event rate). Peak WMSI 1.7
and EF 45% are independent markers of patients at high risk of an adverse clinical
outcome. (J Am Coll Cardiol 2003;42:1084–90) © 2003 by the American College of
Cardiology Foundation
Stress echocardiography is routinely used for the diagnosis
of coronary artery disease (CAD) in patients with anginal
symptoms (1,2). However, an equally important objective of
noninvasive testing is to identify patients at risk of future
cardiac events. The application of prognostic testing is based
on the premise that patients identified as being at highest
risk of adverse outcomes can be intervened upon to alter the
natural history of their disease process, thereby reducing
subsequent risk. Prospective, randomized clinical trials have
shown that medical therapy and coronary revascularization
can reduce cardiac mortality in subsets of selected patients
(3,4). Recent trials of medical therapy have demonstrated
reductions in both fatal and non-fatal myocardial infarction
(MI) rates and cardiac death (5–9).
Stress echocardiographic results are traditionally inter-
preted as binary (normal or abnormal). Risk stratification
and prognosis based on this approach indicate that a normal
study portends a good prognosis (low risk), and an abnormal
study is associated with an increased risk of cardiac events
(high risk). However, abnormal stress echocardiographic
studies should be further risk stratified: a patient with only
apical ischemia (single-vessel CAD) is at substantially lower
(intermediate) risk than a patient with both anterior and
inferolateral ischemia and cavity dilation after stress (mul-
tivessel CAD, deemed high risk). Thus, if stress echocardi-
ography could better risk stratify patients into three groups
(low, intermediate, and high risk) and accurately predict
cardiac events, potential cost savings could be realized by
targeting appropriate treatment strategies and more appro-
priate referral to catheterization for the highest risk patients.
Thus, the objectives of the present study were threefold:
1) to define the prognostic value of stress echocardiography
for the prediction of cardiac events; 2) to define the ability
of stress echocardiography to risk stratify patients into low-
(1%/year), intermediate- (1% to 5%/year), and high-risk
(5%/year) groups for cardiac events; and 3) to evaluate the
prognostic value of resting ejection fraction (EF) and peak
left ventricular (LV) wall motion scores, together, in pre-
dicting cardiac events in a large, unselected population of
patients referred for stress echocardiographic testing.
From the Department of Medicine, Division of Cardiology, St. Luke’s–Roosevelt
Hospital Center, Columbia University College of Physicians and Surgeons, New
York, New York. This work was presented in part at the 51st Annual Scientific
Sessions of the American College of Cardiology, Atlanta, Georgia, March 17–20,
2002.
Manuscript received August 9, 2002; revised manuscript received May 16, 2003,
accepted May 21, 2003.
Journal of the American College of Cardiology Vol. 42, No. 6, 2003
© 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00
Published by Elsevier Inc. doi:10.1016/S0735-1097(03)00923-9
METHODS
Study population. We identified 1,607 patients who un-
derwent either exercise or pharmacologic stress echocardi-
ography between January 1, 1996, and November 30, 2000.
Successful follow-up (98%) for cardiac events 1 year after
testing was obtained. Patients with nonischemic cardiomy-
opathy (n  41) were excluded, and patients revascularized
within 60 days after stress echocardiography (n  66) were
censored from the prognostic portion of the analysis, which
left a cohort of 1,500 patients.
Exercise echocardiography protocol. Maximal exercise
treadmill testing was performed using a standard Bruce
protocol. Patients exercised to general fatigue, with prema-
ture termination for severe angina, ventricular tachycardia,
hemodynamically significant arrhythmias, or hemodynamic
instability. Post-exercise echocardiographic images were
acquired within 30 to 60 s after termination of treadmill
exercise. Failure to achieve 85% of the age-predicted max-
imal heart rate was followed by conversion to a dobutamine
stress echocardiographic study (3% to 5% of treadmill
stress echocardiographic studies).
Dobutamine echocardiography protocol. Dobutamine
was administered intravenously beginning at a dose of 5 to
10 g/kg per min and increased by 5 to 10 g/kg per min
every 3 min, up to a maximum of 50 g/kg per min or until
a study end point was achieved. The end points for
termination of the dobutamine infusion included develop-
ment of new segmental wall motion abnormalities, attain-
ment of 85% of age-predicted maximum heart rate, or
development of significant adverse effects related to the
dobutamine infusion. Atropine was administered intrave-
nously in 0.25-mg increments every 3 min, up to a maxi-
mum of 2.0 mg if a study end point was not achieved at the
maximum dobutamine dose.
During both types of stress, transthoracic echocardio-
graphic images were obtained using standard views with
commercially available ultrasound equipment (Hewlett-
Packard Sonos 2500, Andover, Massachusetts). Echocar-
diographic images were acquired at baseline, with each
increment of dobutamine infusion, and during the recovery
phase.
Echocardiographic image analysis. The LV was divided
into 16 segments, as recommended by the American Society
of Echocardiography (10), and a score was assigned to each
segment at baseline, with each stage of stress (dobutamine
only), and during recovery. Each segment was scored as
follows: 1  normal; 2  mild to moderate hypokinesia
(reduced wall thickening and excursion); 3  severe hypo-
kinesia (marked reduced wall thickening and excursion);
4  akinesia (no wall thickening and excursion); and 5 
dyskinesia (paradoxical wall motion away from the center of
the LV during systole) (11). All echocardiograms were
interpreted by the consensus of two experienced echocar-
diographers blinded to the patients’ treatment and outcome.
A normal response to stress was defined as normal wall
motion at rest, with an increase in wall thickening and
excursion during stress. An abnormal response to stress was
defined as: 1) a LV wall segment that did not increase in
thickness and excursion during stress (fixed wall motion
abnormality); 2) deterioration of LV segment wall thicken-
ing and excursion during stress (increase in wall motion
score of 1 grade); and 3) a biphasic response with
dobutamine stress. The peak wall motion score index
(WMSI) following stress was derived from the cumulative
sum score of 16 LV wall segments divided by the number of
visualized segments. The stress echocardiogram with a peak
WMSI of 1.0 was considered normal, 1.1 to 1.7 was mild to
moderately abnormal, and 1.7 was markedly abnormal.
Resting EF used in the study analysis was an average visual
estimation (12) from two experienced echocardiographers.
Patient follow-up. Serial prospective follow-up was ob-
tained by means of a physician-directed telephone interview
using a standardized questionnaire. If the patient died after
the stress echocardiographic study, the closest surviving
relative and the patient’s physician were interviewed to
determine the cause of death. Cardiac death was confirmed
by a review of the hospital medical records and/or death
certificate. Autopsy records were reviewed when available.
The primary end point of the study was the initial
follow-up event: non-fatal MI or cardiac death. Non-fatal
MI was documented by evidence of an appropriate combi-
nation of clinical symptoms, electrocardiographic (ECG)
findings, and cardiac enzyme changes.
Statistical analysis. Continuous data are expressed as the
mean value  SD. Differences in categorical variables
among groups were assessed by chi-square analysis.
Receiver-operating characteristic (ROC) curve analysis was
used to determine the peak WMSI grouping and EF cutoff
value, with the maximal informational content (area beneath
the ROC curve), which optimized accuracy in predicting
cardiac events. Univariate analysis was performed to deter-
mine the relationship between clinical and echocardio-
graphic variables and cardiac events. Univariate variables
that were predictive of cardiac events were considered in the
multivariate logistic regression analysis. Kaplan-Meier cu-
mulative survival analysis with stratification by peak WMSI
and EF was performed; a comparison of survival between
the groups was made using the Mantel-Cox test. Statistical
significance was set at p  0.05. All analyses were per-
formed using commercially available statistical software
(SPSS for Windows, version 10.0.5).
Abbreviations and Acronyms
CAD  coronary artery disease
EF  ejection fraction
LV  left ventricle/ventricular
MI  myocardial infarction
WMSI  wall motion score index
1085JACC Vol. 42, No. 6, 2003 Yao et al.
September 17, 2003:1084–90 Stress Echocardiography: Risk Stratification and Prognosis
RESULTS
Patient characteristics. From the study cohort of 1,500
patients, 514 (34%) underwent treadmill exercise and 986
(66%) underwent pharmacologic stress. The demographics
are characterized in Table 1. Patients who underwent
dobutamine stress were older and more often had a history
of previous MI and bypass surgery, more cardiac risk factors
(hyperlipidemia, hypertension, diabetes, smoking, and fam-
ily history of premature CAD), more frequent abnormal
resting ECGs, a higher peak WMSI, a greater number of
new reversible wall motion abnormalities, worse LV systolic
function, and greater subsequent rates of adverse cardiac
events than patients undergoing exercise stress testing.
Outcome events of stress echocardiography. Patients
were followed for up to five years (mean 2.7  1.0 years),
and 98% of patients were followed for at least one year.
Among the study cohort of 1,500 patients, 75 coronary
events (5%) occurred during the follow-up period. These
included 31 non-fatal MIs (2.1%) and 44 cardiac deaths
(2.9%).
Univariate analysis. Descriptive patient characteristics and
exercise and stress echocardiographic variables in patients
with and without cardiac events on follow-up are shown in
Table 2. Patients with cardiac events on follow-up were
older, more often had a history of previous MI and more
frequent abnormal rest ECGs, and were less likely to
undergo exercise stress (Table 2) than patients without
cardiac events. With respect to echocardiographic variables
(Table 2), patients with cardiac events had a higher peak
WMSI, a greater number of new reversible wall motion
abnormalities, and worse LV systolic function.
Peak WMSI, EF, and cardiac events. The annual cardiac
event rate increased as a function of the extent and severity
of abnormal wall motion response during stress and increas-
ing peak WMSI (Fig. 1). A normal wall motion (peak
WMSI  1.0) response during stress echocardiography was
associated with a benign prognosis (0.9%/year), whereas
mild to moderate (peak WMSI 1.1 to 1.7) and severe wall
motion (peak WMSI1.7) abnormalities resulted in higher
cardiac event rates (3.1%/year and 5.2%/year, respectively; p
 0.0001 vs. normal wall motion). Figure 2 illustrates the
cardiac event rate as a function of peak WMSI and EF. An
EF 45% demonstrated an intermediate cardiac event rate,
even in patients with a peak WMSI of 1.1 to 1.7 (2.0%/
year) or 1.7 (2.3%/year). An EF 45% and peak WMSI
of 1.1 to 1.7 (6.2%/year) or 1.7 (5.6%/year) were associ-
ated with a high cardiac event rate. There is a significant
correlation between peak WMSI and EF (r  0.83, p 
Table 1. Patient Characteristics by Type of Stress
Exercise Stress
(n  514)
Dobutamine
(n  986) p Value
Age (yrs) 54  12 61  12 0.0001
Male gender 273 (53%) 489 (49%) 0.49
History of MI 43 (8%) 205 (21%) 0.0001
History of PCI 39 (7%) 89 (9%) 0.40
History of bypass
surgery
29 (5%) 103 (10%) 0.01
History of hypertension 281 (55%) 690 (71%) 0.01
History of diabetes 99 (19%) 301 (31%) 0.0001
Number of cardiac risk
factors
1.7  1.1 1.9  1.1 0.001
Beta-blockers 106 (20%) 242 (25%) 0.16
Abnormal rest ECG 170 (34%) 480 (49%) 0.0001
%Max HR (beats/min) 95  10 87  13 0.0001
Peak wall motion score
index
1.1  0.3 1.4  0.7 0.0001
Number of new
reversible wall
motion abnormalities
0.8  2.3 2.2  3.2 0.0001
Ejection fraction (%) 57  5 51  13 0.0001
Follow-up (yrs) 2.7  0.9 2.7  0.9 0.22
Myocardial infarction 4 (1%) 27 (3%) 0.02
Cardiac death 4 (1%) 39 (4%) 0.001
Data are presented as the mean value  SD or number (%) of patients.
ECG  electrocardiogram; %Max HR  percent maximal predicted-heart rate
achieved; MI  myocardial infarction; PCI  percutaneous coronary intervention.
Table 2. Patient Characteristics
Cardiac
Events
(n  75)
No Events
(n  1425) p Value
Age (yrs) 64  12 58  12  0.01
Male gender 43 (57%) 719 (50%) 0.58
History of hypertension 57 (79%) 914 (65%) 0.35
History of diabetes 28 (38%) 372 (26%) 0.06
History of MI 25 (36%) 223 (16%)  0.001
Abnormal rest ECG 48 (69%) 602 (44%) 0.03
Exercise 5 (6%) 476 (33%)  0.0001
Peak wall motion score index 1.8  0.9 1.2  0.6  0.0001
Number of new reversible wall
motion abnormalities
4.2  4.7 1.6  3.4  0.001
Ejection fraction (%) 43  19 54  10  0.0001
Data are presented as the mean value  SD or number (%) of patients.
Abbreviations as in Table 1.
Figure 1. Cardiac event rate per year as a function of wall motion score
index (WMSI). The number of patients within each WMSI category is
shown below each column. Statistical significance increases as a function
of the WMSI result.
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0.0001), such that a higher peak WMSI was associated with
a lower resting EF.
Exercise versus dobutamine stress. There were eight car-
diac events among patients who underwent treadmill stress
and 67 events among patients who underwent dobutamine
stress (0.6%/year vs. 2.5%/year, p  0.0001). Patients with
EF 45% had significantly higher cardiac event rates, both
in the exercise and dobutamine groups. Patients with
abnormal exercise or abnormal dobutamine stress studies
had significantly higher cardiac event rates than correspond-
ing patients with normal exercise (1.4%/year vs. 0.2%/year,
p  0.05) or normal dobutamine (4.7%/year vs. 0.8%/year,
p  0.0001) studies.
Predictors of cardiac events. Univariate predictors of car-
diac events are shown in Table 3. Clinical and echocardio-
graphic variables significant by univariate analysis were
considered in the multivariate analysis. On multivariate
logistic regression analysis, peak WMSI (relative risk [RR]
2.1, 95% confidence interval [CI] 1.0 to 4.4; p  0.04) and
EF (RR 1.0, 95% CI 0.9 to 1.0; p  0.01) were both
predictors of cardiac events.
Kaplan-Meier survival analysis: risk stratification using
peak WMSI and EF. Figures 3 and 4 show cumulative
survival curves in patients as a function of peak WMSI
(Fig. 4) abnormalities and EF. A peak WMSI of 1.0 or EF
45% identified patients at low risk. Cumulative survival
was progressively worse with a higher peak WMSI. A peak
WMSI1.7 or EF45% identified patients at highest risk
of cardiac events.
DISCUSSION
This study assessed the prognostic value of stress echocar-
diography in patients with known or suspected CAD. A
normal stress echocardiographic study portends an excellent
prognosis. Univariate regression showed that peak WMSI
and EF were independent predictors of cardiac events.
Stress echocardiography can risk stratify patients not only
into high- and low-risk groups, but also into an intermedi-
ate risk group (1% to 5%) for cardiac events. Findings from
this study show that peak WMSI 1.7 and EF 45%
identified patients at highest risk of adverse cardiac events.
Prognostic implications of a normal stress echocardio-
gram. Previous studies have examined the prognostic value
of a normal stress echocardiogram (13–21). It has been
demonstrated that normal stress echocardiography is asso-
ciated with a benign prognosis (16,20,21). However, a few
studies have reported intermediate cardiac event rates in
patients with a normal stress echocardiogram (13–15,17–
19). These studies with higher event rates included patients
with resting wall motion abnormalities and were performed
before the routine use of harmonic imaging and contrast
agents. The results of the present study are concordant with
current published data in that a normal stress echocardio-
gram confers a benign prognosis. This low event rate of
0.9%/year over the ensuing year approaches that of a normal
age-matched population and also of patients with normal
coronary angiograms (22). The higher cardiac event rates in
patients undergoing dobutamine stress are related to the
worse clinical, wall motion, and overall LV systolic function
characteristics of these patients (Table 1). The results of the
present study compare favorably with those of normal
myocardial perfusion studies (thallium-201 or technetium-
99m sestamibi), associated with a benign prognosis (23).
Prognostic value of peak WMSI: risk stratification. The
diagnosis of CAD is the first step in the appropriate
evaluation of a patient with anginal symptoms. However,
for proper management and appropriate decision analysis,
additional information on risk stratification and prognosis is
necessary (24). Peak WMSI is quantitated by stress echo-
cardiographic interpretation and incorporates both the ex-
tent and severity of wall motion abnormalities at peak stress.
In this study, peak WMSI was able to effectively risk stratify
patients into three groups: low- (0.9%/year), intermediate-
Figure 2. Cardiac event rate per year as a function of wall motion score
index and ejection fraction (EF). The number of patients within each
category is indicated below each column. Shaded columns  EF 45%;
solid columns  EF 45%.
Table 3. Univariate and Multivariate Predictors of
Cardiac Events
Variable RR 95% CI p Value
Univariate predictors of
cardiac events
Age 0.96 0.94–0.98 0.001
Hypertension 1.99 1.11–3.56 0.01
Diabetes mellitus 1.74 1.06–2.83 0.02
Smoking 1.62 0.99–2.64 0.05
History of MI 2.91 1.74–4.85 0.0001
Abnormal rest ECG 2.82 1.67–4.77 0.0001
%Max HR 1.02 1.00–1.04 0.004
Ejection fraction 1.05 1.03–1.06 0.0001
Peak WMSI 4.64 2.87–7.53 0.0001
Multivariate predictors
of cardiac events
Peak WMSI 2.08 1.01–4.42 0.04
Ejection fraction 0.97 0.94–0.99 0.01
CI  confidence interval; RR  risk ratio; other abbreviations as in Table 1.
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(3.1%/year), and high-risk (5.2%/year) groups for cardiac
events.
Prognostic value of EF. Multiple studies have shown that
EF is a powerful predictor of cardiac events (25,26).
Angiographically measured EF has been previously reported
as a better predictor of survival, compared with the angio-
graphically demonstrated number of diseased coronary ves-
sels in medically treated patients (26). In the present study,
an EF threshold of 45% provided appropriate further risk
stratification of patients. Patients with an EF 45% had a
low to intermediate cardiac event rate, regardless of the
extent of peak WMSI abnormality.
Peak WMSI and EF data provided appropriate risk
stratification of patients undergoing stress echocardiogra-
phy. Peak WMSI and EF were concordantly identified by
multivariate analyses as the best predictors of cardiac events.
Of note, there were 22 patients with a peak WMSI of 1.0
and EF 45%. These patients had resting global LV
hypokinesia but a normal peak WMSI of 1.0 (inotropic
contractile reserve), suggestive of nonischemic cardiomyop-
athy. Despite normal peak WMSI, a worse prognosis was
conferred in the subgroup of patients with EF 45%.
Study significance and implications for the use of stress
echocardiographic testing. In contrast to previous studies
(27–34) assessing the prognostic value of wall motion or EF
variables, this is the first study to evaluate risk stratification
and prognosis together in a large patient population referred
for stress echocardiography. This is the first stress echocar-
diographic study to define an intermediate-risk group and
demonstrate risk stratification into three groups (low-,
intermediate-, and high-risk groups). This study incorpo-
rates wall motion and EF into prognostic risk stratification
Figure 3. Cumulative survival as a function of wall motion score index (WMSI) using cardiac events as an end point.
Figure 4. Cumulative survival stratified into ejection fraction (EF) 45% and EF 45% using cardiac events as an end point.
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as separate and combined end points. Thus, the results of
this study may be applicable to the general population of
patients typically referred for stress echocardiography.
In the present study, the presence of normal wall motion
(peak WMSI  1.0) during stress echocardiography con-
ferred a benign prognosis. These low-risk patients generally
only require counseling with regard to risk factor modifica-
tion. Patients with mild to moderate wall motion abnor-
malities (peak WMSI 1.1 to 1.7) had an intermediate risk
of cardiac events. The ideal management strategy for these
patients is unclear. Rather than an invasive management
approach of catheterization and revascularization, with its
inherent risks, patients with an intermediate risk of cardiac
events may perhaps experience lowering of their risk of
future cardiac events by aggressive risk factor modification
and referral to catheterization, only if they have refractory
symptoms. In addition, resting EF should have an impor-
tant influence on the appropriate management approach in
such patients. An initial noninvasive management strategy
may be cost-effective and avoid unnecessary invasive proce-
dures (35). Conversely, high-risk patients with WMSI1.7
and especially those with EF 45% are at a significant risk
of cardiac events. Such high-risk patients should be appro-
priately referred for consideration of cardiac catheterization
and potential coronary revascularization to modify and
reduce their risk.
Study limitations. The prognostic analysis of the study was
limited by the study population. Among the 1,500 patients
included in this study, 1,075 (71.6%) had a normal response
to stress (WMSI  1.0). There were only 75 coronary
events (1.9%/year) during the follow-up period. Thus, due
to a limited number of hard events, the study combined
analysis of exercise and dobutamine stress patients. This is
not ideal, but probably acceptable, as patients could be
individually risk stratified (abnormal vs. normal) by either
exercise or dobutamine stress echocardiographic studies. In
addition, although patients were followed for up to five
years, one-year follow-up was incomplete in 2% of patients.
Furthermore, this low-risk patient population provided a
limited number of patients with WMSI of 1.1 to 1.7 and
1.7 for substratification by EF. The frequency of cardiac
death was higher than that of non-fatal MI in this popula-
tion. This unexpected finding may be due to difficulty in
confirming MI and our higher success rate in defining
cardiac death in each patient. Another potential limitation is
that the cutoff values for WMSI and EF in this study could
be subject to patient referral bias relative to the constitution
of our patient population.
The patients in this study were typical in terms of age,
gender, and demographics of a population referred for
testing at a large tertiary-care hospital, and the results may
be generalizable to this setting. However, the subjective
nature of wall motion analysis and visual EF measurement,
with its dependence on the expertise of the observer,
presents a limitation with respect to the extrapolation of our
results to those of other centers (36,37).
Conclusions. On the basis of this and other reported
studies, it is clear that a normal stress echocardiogram
confers a benign prognosis (1%/year). Peak WMSI can
effectively risk stratify patients into low- (0.9%/year),
intermediate- (3.1%/year), and high-risk (5.2%/year) groups
for cardiac events. Resting EF, as assessed by echocardiog-
raphy, provides further risk stratification of patients
with known or suspected CAD, in addition to peak
WMSI alone. Thus, the information provided by stress
echocardiography, peak WMSI, and EF should be used
together in identifying high-risk patients for appropriate
referral to catheterization and consideration of coronary
revascularization.
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